<DOC>
	<DOCNO>NCT01599000</DOCNO>
	<brief_summary>In 2009 , Papua New Guinea officially adopt artemether-lumefantrine ( AL ) new national first-line drug uncomplicated malaria . The principal purpose study measure absolute effectiveness AL use real-life clinical condition , compare optimize in-vivo trial condition . This question raise National Department Health preparation country-wide roll-out AL . The study design randomize control trial compare two study arm . Patients `` effectiveness arm '' receive first dose AL full supervision clinic ; follow dos take home , real-life clinical practice accord new national treatment guideline . Patients `` efficacy arm '' receive dos AL directly observe treatment clinic order establish efficacy drug use ideal condition . The study enroll outpatient age 6 month 10 year history fever positive rapid test malaria . Patients meet enrollment criterion provide full write informed consent parent/caretaker randomize either two study arm . Patients arm follow actively 42 day . Patients efficacy arm schedule visit day 0 , 1 , 2 , 3 , 7 , 14 , 28 42 ; patient effectiveness arm day 0 , 3 , 7 , 14 , 28 42 .</brief_summary>
	<brief_title>Artemether-Lumefantrine Clinical Effectiveness Study</brief_title>
	<detailed_description />
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Age 6 month 10 year ( +/ 1 month child without know date birth ) Permanent resident study area Not enrol another study time No known history hypersensitivity reaction artemether lumefantrine History fever previous 72 hour ( approximate ) Rapid diagnostic test ( RDT ) positive specie Plasmodium General danger sign : inability drink breastfeed , vomit everything , recent history convulsion , lethargy unconsciousness , inability sit stand Signs severe malaria ( impaired consciousness , respiratory distress , circulatory collapse , abnormal bleeding , jaundice , determine clinician ) Severe malnutrition : define child whose weightforheight 3 standard deviation less 70 % median NCHS/WHO normalize reference value , symmetrical oedema involve least foot ; middle upper arm circumference 12 cm Clinically significant concomitant disease require admission Contraindications mention national treatment guideline</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>malaria</keyword>
	<keyword>Plasmodium</keyword>
	<keyword>Papua New Guinea</keyword>
	<keyword>artemether/lumefantrine</keyword>
</DOC>